Enliven Therapeutics, Inc. (ELVN)
47.54
-1.26
(-2.58%)
USD |
NASDAQ |
Nov 16, 16:00
47.54
0.00 (0.00%)
After-Hours: 20:00
Enliven Therapeutics Enterprise Value : 2.707B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 2.707B |
| November 12, 2026 | 2.671B |
| November 11, 2026 | 2.882B |
| November 10, 2026 | 2.883B |
| November 09, 2026 | 2.909B |
| November 06, 2026 | 2.753B |
| November 05, 2026 | 2.412B |
| November 04, 2026 | 2.593B |
| November 03, 2026 | 2.415B |
| November 02, 2026 | 2.400B |
| October 30, 2026 | 2.372B |
| October 29, 2026 | 2.433B |
| October 28, 2026 | 2.411B |
| October 27, 2026 | 2.331B |
| October 26, 2026 | 2.169B |
| October 23, 2026 | 2.171B |
| October 22, 2026 | 2.201B |
| October 21, 2026 | 2.193B |
| October 20, 2026 | 2.151B |
| October 19, 2026 | 1.964B |
| October 16, 2026 | 1.862B |
| October 15, 2026 | 2.010B |
| October 14, 2026 | 2.006B |
| October 13, 2026 | 2.022B |
| October 12, 2026 | 2.121B |
| Date | Value |
|---|---|
| October 09, 2026 | 2.131B |
| October 08, 2026 | 2.106B |
| October 07, 2026 | 2.159B |
| October 06, 2026 | 2.235B |
| October 05, 2026 | 2.462B |
| October 02, 2026 | 2.572B |
| October 01, 2026 | 2.516B |
| September 30, 2026 | 2.489B |
| September 29, 2026 | 2.513B |
| September 28, 2026 | 2.477B |
| September 25, 2026 | 2.384B |
| September 24, 2026 | 2.415B |
| September 23, 2026 | 2.483B |
| September 22, 2026 | 2.636B |
| September 21, 2026 | 2.686B |
| September 18, 2026 | 2.729B |
| September 17, 2026 | 2.787B |
| September 16, 2026 | 2.704B |
| September 15, 2026 | 3.015B |
| September 14, 2026 | 3.093B |
| September 11, 2026 | 3.085B |
| September 10, 2026 | 3.225B |
| September 09, 2026 | 3.315B |
| September 08, 2026 | 3.455B |
| September 04, 2026 | 3.452B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Definium Therapeutics, Inc. | 3.381B |
| Cocrystal Pharma, Inc. | 12.61M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -104.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.70M |
| Total Expenses (Quarterly) | 27.70M |
| EPS Diluted (Quarterly) | -0.3552 |
| Earnings Yield | -3.57% |
| Normalized Earnings Yield | -3.574 |